Anti-hnRNP A1 (citrulline R122) antibody [EPR20177]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(1 Publication)
Rabbit Recombinant Monoclonal hnRNP A1 citrulline R122 antibody. Suitable for IP, Dot, WB and reacts with Human, Synthetic peptide, Transfected cell lysate - Human samples. Cited in 1 publication.
View Alternative Names
HNRPA1, HNRNPA1, Heterogeneous nuclear ribonucleoprotein A1, hnRNP A1, Helix-destabilizing protein, Single-strand RNA-binding protein, hnRNP core protein A1
- IP
Supplier Data
Immunoprecipitation - Anti-hnRNP A1 (citrulline R122) antibody [EPR20177] (AB208029)
hnRNP A1 (citrulline R122) was immunoprecipitated from 0.35 mg of HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) transfected with GFP-tagged PADI4 (WT) expression vector, treated with 10 mM calcium chloride and 10 μM Ionomycin for 2 hours whole cell lysate with ab208029 at 1/40 dilution. Western blot was performed from the immunoprecipitate using ab208029 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.
Lane 1 : HEK-293T transfected with GFP-tagged PADI4 (WT) expression vector, treated with 10 mM calcium chloride and 10 μM Ionomycin for 2 hours whole cell lysate 10 μg (Input).
Lane 2 : ab208029 IP in HEK-293T transfected with GFP-tagged PADI4 (WT) expression vector, treated with 10 mM calcium chloride and 10 μM Ionomycin for 2 hours whole cell lysate.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab208029 in HEK-293T transfected with GFP-tagged PADI4 (WT) expression vector, treated with 10 mM calcium chloride and 10 μM Ionomycin for 2 hours whole cell lysate.
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 30 seconds.
All lanes:
Immunoprecipitation - Anti-hnRNP A1 (citrulline R122) antibody [EPR20177] (ab208029)
Predicted band size: 38 kDa
false
- WB
Supplier Data
Western blot - Anti-hnRNP A1 (citrulline R122) antibody [EPR20177] (AB208029)
Blocking/Dilution buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-hnRNP A1 (citrulline R122) antibody [EPR20177] (ab208029) at 1/2000 dilution
Lanes 1 and 3:
HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) transfected with a control vector containing GFP tag, treated with 10 mM calcium chloride and 10 at 20 µg
Lane 2:
HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) transfected with GFP-tagged PADI2 (WT) expression vector, treated with 10 mM calcium chloride and at 20 µg
Lane 4:
HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) transfected with GFP-tagged PADI4 (WT) expression vector, treated with 10 mM calcium chloride and at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 38 kDa
true
Exposure time: 8s
- Dot
Supplier Data
Dot Blot - Anti-hnRNP A1 (citrulline R122) antibody [EPR20177] (AB208029)
Dot blot analysis of hnRNP A1 (citrulline R122) labeled with ab208029 at 1/1000 dilution.
Lane 1 : hnRNP A1 (citrulline R122) peptide;
Lane 2 : hnRNP A1 non-citrulline peptide;
Lane 3 : hnRNP A2B1 (citrulline R129) peptide.
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution was used as secondary antibody.
Blocking/Dilution buffer : 5% NFDM/TBST.
Exposure time : 3 minutes.
Based on sequence homology this antibody cross reacts with hnRNP A2B1 (citrulline R129) and hnRNP A1L2 (citrulline R122).
Related conjugates and formulations (1)
-
Anti-hnRNP A1 (citrulline R122) antibody [EPR20177] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
HnRNP A1 is involved in RNA binding and splicing contributing to the formation of spliceosomes the complexes responsible for pre-mRNA splicing. The protein aids in alternative splicing influencing mRNA diversity and stability. hnRNP A1 interacts with other proteins in the hnRNP family remodeling ribonucleoprotein complexes and affecting their functions. These interactions ensure proper mRNA maturation impacting gene expression regulation within the cell.
Pathways
HnRNP A1 is integral to critical cellular mechanisms such as the regulation of mRNA transport and splicing. It influences the DNA damage response pathway by modulating gene expression required for cellular repair and stability. hnRNP A1 also cooperates with other RNA binding proteins like the splicing factors SR proteins to orchestrate the splicing machinery. These interactions are pivotal in maintaining cellular homeostasis and response to stress.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (1)
Recent publications for all applications. Explore the full list and refine your search
Bladder cancer (Amsterdam, Netherlands) 9:29-40 PubMed38994477
2023
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com